NCT06475989 2026-03-02
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Eastern Cooperative Oncology Group
Phase 3 Recruiting
Clinical Trials
24 trialsNCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT04675710 2026-02-19
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04940052 2025-12-02
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT03975231 2025-11-10
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06195228 2025-08-14
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
Phase 4 Recruiting
NCT03085056 2025-07-03
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04238624 2025-07-02
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07010393 2025-06-08
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Phase 4 Not yet recruiting
NCT05275374 2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2 Not yet recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT06362694 2024-04-12
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT05182931 2023-10-31
I-FIRST
Olivia Newton-John Cancer Research Institute
Phase 2 Unknown
NCT06079333 2023-10-12
NEO-ATACT
Leiden University Medical Center
Phase 2 Recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT04619316 2023-06-22
ERRITI
University Hospital, Essen
Phase 2 Unknown
NCT03244956 2021-09-28
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT04554680 2021-03-05
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
National University Hospital, Singapore
Phase 2 Unknown
NCT01438554 2018-08-29
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02538627 2017-09-05
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Merrimack Pharmaceuticals
Phase 1 Terminated
NCT01553851 2016-12-26
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Washington University School of Medicine
Phase 2 Completed